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metabolism and its age-associated dysregulation
Mark T Mc Auley1*†, Darren J Wilkinson2†, Janette JL Jones3† and Thomas BL Kirkwood1†Abstract
Background: Global demographic changes have stimulated marked interest in the process of aging. There has
been, and will continue to be, an unrelenting rise in the number of the oldest old ( >85 years of age). Together
with an ageing population there comes an increase in the prevalence of age related disease. Of the diseases of
ageing, cardiovascular disease (CVD) has by far the highest prevalence. It is regarded that a finely tuned lipid profile
may help to prevent CVD as there is a long established relationship between alterations to lipid metabolism and
CVD risk. In fact elevated plasma cholesterol, particularly Low Density Lipoprotein Cholesterol (LDL-C) has
consistently stood out as a risk factor for having a cardiovascular event. Moreover it is widely acknowledged that
LDL-C may rise with age in both sexes in a wide variety of groups. The aim of this work was to use a whole-body
mathematical model to investigate why LDL-C rises with age, and to test the hypothesis that mechanistic changes
to cholesterol absorption and LDL-C removal from the plasma are responsible for the rise. The whole-body
mechanistic nature of the model differs from previous models of cholesterol metabolism which have either focused
on intracellular cholesterol homeostasis or have concentrated on an isolated area of lipoprotein dynamics. The
model integrates both current and previously published data relating to molecular biology, physiology, ageing and
nutrition in an integrated fashion.
Results: The model was used to test the hypothesis that alterations to the rate of cholesterol absorption and
changes to the rate of removal of LDL-C from the plasma are integral to understanding why LDL-C rises with age.
The model demonstrates that increasing the rate of intestinal cholesterol absorption from 50% to 80% by age 65
years can result in an increase of LDL-C by as much as 34 mg/dL in a hypothetical male subject. The model also
shows that decreasing the rate of hepatic clearance of LDL-C gradually to 50% by age 65 years can result in an
increase of LDL-C by as much as 116 mg/dL.
Conclusions: Our model clearly demonstrates that of the two putative mechanisms that have been implicated in
the dysregulation of cholesterol metabolism with age, alterations to the removal rate of plasma LDL-C has the most
significant impact on cholesterol metabolism and small changes to the number of hepatic LDL receptors can result
in a significant rise in LDL-C. This first whole-body systems based model of cholesterol balance could potentially be
used as a tool to further improve our understanding of whole-body cholesterol metabolism and its dysregulation
with age. Furthermore, given further fine tuning the model may help to investigate potential dietary and lifestyle
regimes that have the potential to mitigate the effects aging has on cholesterol metabolism.* Correspondence: mcaulem@hope.ac.uk
†Equal contributors
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Lipid metabolism has a key role to play in human lon-
gevity and healthy ageing. This has been emphasized by
recent genetic studies examining the lipoprotein pheno-
type in individuals with exceptional longevity [1,2]. It is
highly probable such subjects with exceptional longevity
and favourable lipoprotein profiles have avoided CVD.
CVD is the primary cause of mortality in developed
countries, with almost 40% of males and 30% of females
in the United Kingdom over the age of 85 years living
with the condition [3]. Of the components of lipid me-
tabolism, elevated LDL-C has consistently stood out as a
risk factor for CVD [4]. This cholesterol sub-fraction has
been connected to atherosclerosis, a process regarded as
the underlying pathogenesis for coronary heart disease
(CHD) and stroke, the leading forms of CVD [5]. Studies
have repeatedly demonstrated that regardless of physical
activity levels and nutritional status, LDL-C has been
shown to rise with age in both males and females in a
diverse range of groups [6,7]. Understanding why LDL-C
rises with age is complex; nevertheless rodent studies
have indicated that increases in intestinal cholesterol ab-
sorption or possibly a decrease in the plasma clearance
rate of LDL-C may have a mechanistic role to play
[8-10]. In this paper we examine the hypothesis that
these two mechanisms are central to understanding
why LDL-C increases with age. To test this hypothesis
a number of steps were required. Firstly, it was neces-
sary to study both intestinal cholesterol absorption
and LDL-C plasma clearance within an integrative
framework which incorporated the other fundamental
biological components of this complex system [11,12].
This required incorporating the interactions of the in-
dividual elements of this system. Secondly, it was im-
portant to investigate changes both to intestinal
cholesterol absorption and LDL-C clearance over an
extended period of time. Clearly it would have been
difficult to test our hypothesis within this framework
using conventional in vivo or in vitro techniques as
such approaches can be resource intensive, expensive,
time consuming, unpractical and potentially unethical
[13]. Furthermore, whole-body cholesterol metabolism
is a complex system with a variety of non-linear inter-
actions among its various components, including both
positive and negative feedback and complex crosstalk
between elements such as cholesterol synthesis and
absorption [14].
Utilizing a mechanistic mathematical model offered
an alternative means of overcoming these difficulties
and presented a cheap, ethical and practical way of in-
vestigating our hypothesis [13]. However, as existing
computational models of cholesterol metabolism were
either of an intracellular nature, lipoprotein kinetic
focused, or compartmental in nature, they failed toincorporate the ageing process or address the holistic
nature of our question and were thus determined to be
unsuitable [15,16]. Consequently we constructed a
whole-body mathematical model of cholesterol metab-
olism which was used to explore changes to both the
rate of intestinal cholesterol absorption and the hepatic
rate of clearance of LDL-C from the plasma. The
model showed that of these two mechanisms, changes
to the rate of LDL-C removal from the plasma with
age had the most significant effect on cholesterol me-
tabolism. The model was constructed using a series of
coupled ordinary differential equations (ODEs). Addition-
ally, the model was coded in the systems biology markup
language (SBML) format and submitted to the Biomodels
database to facilitate its updating and future exchange
[17,18]. To build the model a wide variety of data was
used including previously published data from a range of
fields such as molecular biology, nutrition, physiology and
biochemistry.
Whole-body cholesterol metabolism
Cholesterol has a vital role to play in the human body. It
is a key constituent of all cell membranes being involved
in membrane fluidity; it is the precursor of steroid hor-
mones which control a range of physiological functions,
and bile salts, which are necessary for the intestinal ab-
sorption of cholesterol, fats and lipid soluble vitamins
[19,20]. The mechanisms underpinning cholesterol me-
tabolism interact to preserve the balance of cholesterol
in the body. This balance is maintained by coordinated
interactions between cholesterol absorption, excretion
and synthesis.
Intake, absorption and excretion
Cholesterol from both the diet and bile is taken up by
the small intestine daily. Cholesterol absorption is an in-
efficient process and can vary significantly from person
to person. The percentage of cholesterol absorbed in
healthy subjects (both male and female) is in the range
of 29-80% [21]. The heterogeneity in cholesterol absorp-
tion has been attributed to its complexity, which
involves a large number of enzymes and transport pro-
teins in a multi-step process, however the way these
mechanisms interact to regulate absorption efficiency
remains unknown [22]. It is clear that during digestion,
bile acids are released from the liver and gall bladder
into the intestine and as cholesterol is practically insol-
uble in aqueous environments, the bile acids serve to
create lipid micelles [23]. The micelles are then trans-
ported to the brush border of jejunal enterocytes, where
the cholesterol is transferred into the enterocytes. At this
point the story becomes nebulous, as the mechanism(s)
by which micellar cholesterol is absorbed through the
brush border membranes independent of bile salt uptake
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that cholesterol absorption occurs by passive diffusion
down a concentration gradient [24,25]. However, recent
evidence supports the hypothesis that protein facilitated
mechanisms are involved in cholesterol uptake by the
enterocyte [26,27]. When cholesterol is inside entero-
cytes, it has been suggested that it can be transported
back to the intestinal lumen by a class of membrane
proteins known as adenosine triphosphate binding cas-
sette transporters. It has been proposed that these trans-
porters may serve to efflux cholesterol from the
enterocyte back into the intestinal lumen for excretion
[28]. Although the precise mechanisms of cholesterol
absorption are not yet fully understood, it is known that
cholesterol not transported back to the intestinal lumen
is esterified in the enterocyte by acyl-CoA-cholesterol
acyltransferase (ACAT), assembled and packaged, to-
gether with triglycerides, into chylomicrons. Chylomi-
crons are just one of many lipid carriers, known as
lipoproteins, found in the circulation of mammals.
According to their density, lipoproteins are categorised
as chylomicrons, very low density lipoproteins (VLDL),
intermediate density lipoproteins (IDL), low density lipo-
proteins (LDL) and high density lipoproteins (HDL)
[29]. Chylomicrons transport absorbed cholesterol via
the lymph to the liver [30].
The liver and whole-body cholesterol metabolism
The liver is the central organ involved in cholesterol
metabolism. It is actively involved in the uptake of
cholesterol from lipoproteins, is an important site for
de novo synthesis and is capable of storing cholesterol
as esters after esterification by ACAT. Furthermore, it
is involved in the secretion of cholesterol-containing
lipoproteins and is the sole organ capable of removing
excess cholesterol from the body, either by secretion
into bile or by conversion into bile acids [31]. Bile acids
are synthesised from cholesterol in the liver and facili-
tate the solubilisation of cholesterol, a prerequisite for
cholesterol absorption. Bile acids are released postpran-
dially and will not solubilise dietary lipids unless above
a critical concentration. The concentration gradient is
generated by two factors. Firstly, bile acids are powerful
acids that are impermeable to cell membranes. Sec-
ondly, the majority of bile acids are reabsorbed from
the small intestine and return to the liver via the portal
vein, where they are taken up by hepatocytes and re-
secreted into bile [32]. The conservation of bile acids
by active absorption from the small intestine results in
a hepatic pool of bile acids that cycles several times
with each meal. In humans, the bile acids circulate be-
tween six and 10 times per day, while around 400 mg
of bile acids is lost daily through faecal excretion.
A decreased return of bile acids to the liver iscompensated for by increased de novo synthesis from
cholesterol in order to maintain the bile salt pool [33].
Cholesterol not converted to bile acids or secreted into
bile can be released from the liver into the circulation
and transported to peripheral tissue. The liver secretes
VLDLs and on entering the circulation VLDLs are
hydrolysed by lipoprotein lipase (LPL) [34], leading to
the formation of VLDL remnants and IDLs. IDLs are
either taken up by the liver or further hydrolysed to
LDLs, which are the main cholesterol carrier in the
blood [35]. LDL is taken up by the liver or by periph-
eral cells, either independently or via the LDL-receptor
(LDLR). Expression is high in the liver but LDLRs are
also expressed in peripheral tissue [36,37]. Hepatic
LDLR (HLDLR) expression is transcriptionally regulated
in response to intracellular cholesterol levels [38].
Reverse cholesterol transport
The flux of cholesterol from peripheral tissue to the
liver is known as reverse cholesterol transport (RCT).
This pathway plays a vital role in maintaining choles-
terol balance, with its action resulting in the movement
of cholesterol from peripheral tissue to the liver [39].
Consequently RCT presents the only route for excess
cholesterol generated in peripheral tissue to be elimi-
nated from the body. HDL plays a crucial part in RCT
[40,41]. HDL synthesis takes place in the liver and in-
testine, commencing with the generation of nascent
particles, small discoidal structures lacking cholesterol.
HDL acquires free cholesterol from the cell membranes
of several tissues, which is esterified by the action of
lecithin:cholesterol acyltransferase (LCAT), resulting in
cholesteryl ester-rich, mature HDL particles. The trans-
port of high density lipoprotein cholesterol (HDL-C) to
the liver may follow several routes. In the presence of
the enzyme cholesteryl ester transport protein (CETP),
a portion of cholesterol esters from the HDL particle
can be redistributed to other lipoproteins (e.g. VLDL
and LDL) in exchange for triglyceride [42]. This choles-
terol is delivered back to the liver via the LDLR. An
alternative route involves the mature HDL particle
binding directly to scavenger receptors BI (SR-BI) on
the liver [43].
Cholesterol synthesis
Almost all the tissues in the body are capable of synthesiz-
ing cholesterol from acetyl-Co enzyme A (CoA) in a series
of enzyme-mediated steps that are mainly restricted to the
endoplasmic reticulum (ER). The major rate-controlling
enzyme in this pathway is 3-hydroxy-3-methylglutaryl
CoA (HMG-CoA) reductase. Cholesterol homeostasis is
regulated in two ways, firstly, when the content of unester-
ified cholesterol in cells increases, the expression of the
LDLR protein decreases. Furthermore, two key enzymes
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subsequent increase in cellular cholesterol diminishes.
When cholesterol levels fall, these pathways are reacti-
vated [38,44,45].
Dysregulation of cholesterol metabolism with age
The interaction between cholesterol absorption, synthe-
sis, and excretion maintains whole- body cholesterol me-
tabolism. A change to any of them can significantly
influence the others. For example, numerous studies
have shown that inhibition of cholesterol synthesis
results in increased intestinal cholesterol absorption
[46,47]. The close interaction between absorption and
synthesis in maintaining cholesterol balance is consoli-
dated by studies, which have shown that interference
with cholesterol absorption is associated with increased
cholesterol synthesis [47]. Dysregulation of cholesterol
metabolism can lead to high levels of LDL-C, while
population studies have consistently demonstrated that
LDL-C rises with age in both males and females [7]. The
reason for an increase in LDL-C in so many individuals
across both genders remains unknown. Furthermore, the
intrinsic mechanisms that contribute to the rise in LDL-
C with age remain incomplete; however a picture is be-
ginning to emerge of potential candidates. A significant
finding was the discovery that there is a gradual reduc-
tion in the rate of clearance of LDL-C from the circula-
tion with age [48-50]. Adding further to this is the
evidence that the number of hepatic LDLRs (HLDLRs)
diminish with age in certain species [10,50]. Addition-
ally, it has been reported that there is an increase in in-
testinal cholesterol absorption efficiency with age in rats
[8,51]. However, to date no single intrinsic mechanism
or combination of intrinsic mechanisms has conclusively
been attributed to the rise in LDL-C with age [9]. Conse-
quently our whole-body mathematical model investi-
gated the hypothesis that age-related changes to the rate
of intestinal cholesterol absorption and the rate of re-
moval of LDL-C from the plasma could be responsible
for the rise in LDL-C with age in humans.
Results
Results overview
Using the values listed in tables one and two, a sensitiv-
ity analysis was conducted, followed by a number of
simulations that examined the key questions associated
with this research. The model was able to replicate many
of the integral features of whole-body cholesterol bal-
ance and displays qualitative behaviour similar to that
observed in experimental studies [52]. For example,
plasma LDL-C levels rose in response to increases in the
intake of dietary cholesterol, however this was somewhat
more sensitive than that predicted by a meta-analysis of
the experimental literature, as for every 100mg/dayincrease in dietary cholesterol there was a 10mg/dL in-
crease in LDL-C (Figure 1). Changes to cholesterol ab-
sorption were also investigated and the model showed
that for every 10% increment in the rate of cholesterol
absorption, this resulted in a 12.5 mg/dL increase in
LDL-C. Finally, the model was used to investigate the
hypothesis that age related changes to cholesterol ab-
sorption/a decrease in the clearance of LDL-C from the
circulation result in the rise of LDL-C with age. The
model showed that of these two mechanisms, changes
to the rate of removal of LDL-C from the circulation
had the most significant impact on LDL-C levels with
age.
Predictive capability of the model
The model demonstrated that increasing cholesterol ab-
sorption from 50% to 80% and running a simulation
from age 20 years to age 65 years resulted in an increase
of plasma LDL-C by as much as 34 mg/dL (Figure 2,
graph A). However, reducing the number of hepatic LDL
receptors had a profound impact on the system, as an
increase of 116 mg/dL in LDL-C was witnessed by age
65 years in response to a reduction in the number of
these receptors by 50% (Figure 2 graph B). These rises
were compared to that found in population studies
(Figure 2 graphs C and D) with changes to the rate of
clearance of LDL-C clearly having the more significant
impact on LDL-C levels.
Sensitivity analysis-cholesterol absorption
The initial concentrations of the various species are
summarised in Table 1. Where quantitative data was
available, these values reflected the numbers found in
the literature. A sensitivity analysis of the model was
also conducted as the parameter values differ consider-
ably in terms of their magnitude (Table 2) and we
wanted to establish how changes to these parameters
would affect the concentrations of key species. Choles-
terol absorption (k6) is an example of one of the key
parameters that was altered. The initial value of this par-
ameter was set so that 50% of cholesterol entering the
small intestine would be absorbed. However, although
cholesterol absorption is tightly regulated, it is a process
that can vary significantly from one individual to the
next [21]. This range was used to test the sensitivity of
the model to changes in k6. The impact variations in
cholesterol absorption has on LDL-C levels in the model
is shown in (Figure 3).
Sensitivity analysis-dietary cholesterol
A literature review using PubMed revealed the existence
of almost 200 publications containing information relat-
ing to the response of plasma cholesterol to dietary
cholesterol feeding. These investigations were performed
Figure 1 (A-F) The response of the model to changes in the intake of dietary cholesterol compared to a published meta-analysis. A)
The relationship between mean change in dietary cholesterol (mg/day) and mean change in plasma cholesterol levels (mg/dL) in 167 cholesterol
feeding studies published between 1960 and 1999 (McNamara 2000). B-D) The response of the model to changes in dietary cholesterol over a
range of time periods. E) Steady-state levels of LDL-C for various different intakes of dietary cholesterol. F) The change in LDL-C levels in response
to various different values of the parameter k1(cholesterol ingestion). Results of both E&F were generated from a sensitivity analysis of the model
using the software tool Copasi.
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these publications, a meta-analysis by McNamara (2000)
revealed that in response to increased levels of dietary
cholesterol, plasma cholesterol plateaus at high levels of
cholesterol intake [52]. The meta-analysis by McNamara
also reported that the total plasma cholesterol response
to dietary cholesterol is 0.023 mg/dL per mg/day choles-
terol increase (Figure 1, graph A). Of this, 0.019 mg/dL
is in the LDL-C fraction. Therefore, for each 100 mg/
day increase in dietary cholesterol intake in the model, a
1.9 mg/dL increase in LDL-C was expected. Import-
antly, McNamara reported that this increase is inde-
pendent of other types of lipid in the diet and the
baseline plasma cholesterol level. Therefore, the model
was exposed to a decrease of 200 mg/day and increases
of up to 700 mg/day of dietary cholesterol (Figure 1,
graphs A-C). A 10 mg/dL increase in LDL-C was
observed for every 100mg increase in dietary cholesterol
which was 8mg greater than the value predicted in the
meta-analysis by McNamara. We also conducted a sen-
sitivity analysis of the parameter k1 to highlight the dif-
ferent steady-state levels of LDL-C for various intakes ofdietary cholesterol (Figure 1, graphs E&F and Additional
file 1). No increase in HDL-C was observed in response
to changes in dietary cholesterol.
Hypothesis testing- ageing and cholesterol absorption/
LDL-C plasma removal
Aging results in a rise in LDL-C in both sexes (Figure 2,
graphs C and D) [7]. The reason(s) for an increase in
LDL-C in so many individuals across both genders
remains unknown and the issue is the subject of debate
as nutritional status and physical activity levels may dif-
fer within the population sample. The intrinsic mechan-
ism(s) that contribute to the rise in LDL-C with age
remain incomplete; however a picture is beginning to
emerge of potential candidates. As mentioned previ-
ously, rodent studies have shown that cholesterol ab-
sorption efficiency increases markedly with aging [8,21].
It was also mentioned that there is a gradual reduction
in the rate of clearance of LDL-C from the circulation
with age in rodents. Adding further to this is the evi-
dence that the number of hepatic LDLRs diminish with
age in certain species [29]. When cholesterol absorption
Figure 2 (A-E) The relationship between LDL-C and age. The relationship between LDL-C and age A) for males and B) for females. Graphs A
and b were both generated using data from Abbott, Garrison et al. (1983). C) the response of LDL-C in the model to increased cholesterol
absorption. D) The response of LDL-C in the model to decreases in the rate of clearance of LDL-C by hepatic LDLRs. E) Parameter scan for khrs
(daily rate of synthesis of hepatic cholesterol receptors) and its impact on LDL-C levels.
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and 80% by age 65 years, 12, 24 and 34mg/dL increases
respectively, in LDL-C were observed (Figure 2, graph
A). Next, reducing the number of hepatic LDL receptors
(HLDLRs) was investigated. The number of HLDLRs
was reduced in the range 90–50 by age 65 years. This
was done by gradually decreasing the rate of syn-
thesis khrs. This had a significant effect on the model as
LDL-C raised by 116,76,49,26 and 11mg/dL respectively
(Figure 2, graph B). A parameter scan of khrs was also
conducted (Figure 2, graph E).
Discussion
We have constructed a whole-body mathematical
model of cholesterol metabolism using data from a
wide variety of sources and integrated this data withina series of coupled ODEs. Previous computational
models have focused on the intracellular regulation of
cholesterol metabolism [16,53] or have focused on the
metabolic fate of a particular lipoprotein or their recep-
tor mediated endocytosis [54,55], while other mathem-
atical models of lipid metabolism have centred on
compartmental approaches, where by lipoproteins are
represented by compartments [56]. Our model attempts
to include all the major components of whole-body
cholesterol balance and to our knowledge is the first
model of its type built using such a framework. Our
model provides an insight into the complex interplay
of cholesterol metabolism with the aging process. The
model has many areas that require further develop-
ment, however, when the model progresses in the
future it would be worthwhile to investigate how
Table 1 List of species, their abbreviations and their
initial values
Dietary Species Symbol Initial Value
Dietary cholesterol DC 304 mg
Intestinal Species
Intestinal cholesterol IC 3150 mg
Intestinal bile salts IBS 467 mg
Intestinal cholesterol synthesis ICS 0 (Source
Species)
Intestinal nascent high density
lipoprotein synthesis
INHDLS 0 (Source
species)
Excreted Species
Excreted cholesterol EC 0
Excreted bile salts EBS 0
Hepatic Tissue Species
Hepatic cholesterol synthesis HCS 0 (Source
Species)
Hepatic nascent HDL synthesis HNHDLS 0 (Source
Species)
Hepatic bile salt pool HBS 400 mg
Hepatic free cholesterol HFC 60000 mg
Hepatic low density
lipoprotein receptors
HLDLRs 100 (Theoretical
value to represent
the number of hepatic
LDL receptors )
Hepatic low density
lipoprotein receptor
synthesis
HLDLRsS 600 (Source
species)
Hepatic LDL receptors
degradation
HLDLRD 0 (Sink species)
Hepatic cholesterol esters HCE 10000 mg
Scavenger receptor
class B type 1
SRB1 100 (Theoretical
value to
represent
concentration of
SRB1 receptors)
Peripheral Tissue Species
Peripheral low density
lipoprotein receptors
PLDLRs 100 (Theoretical
value)
Peripheral low density
lipoprotein receptors
synthesis
PLDLRsS 575.16 (Source
species)
Peripheral low density
lipoprotein receptors
degradation
PLDLRD 0 (Sink species)
Peripheral free Cholesterol PFC 57516 mg
Peripheral cholesterol esters PCE 9363 mg
Peripheral steroid synthesis PSS 0 (Sink species)
Peripheral cholesterol synthesis PCS 0(Source species)
Plasma Species
Low density lipoprotein
cholesterol
LDLC 100 mg/dL
High density lipoprotein
cholesterol
HDLC 45 mg/dL
Table 1 List of species, their abbreviations and their
initial values (Continued)
Nascent high density
lipoprotein
NHDL 100 (Theoretical
value to represent
the initial number
of Nascent HDL)
Very low density lipoprotein
cholesterol
VLDLC 20 mg/dL
Intermediate density
lipoprotein
cholesterol
IDLC 20 mg/dL
Cholesteryl ester transfer
protein
CETP 100 (Fixed boundary
condition)
Lecithin:cholesterol
acyltransferase
LCAT 100 (Fixed boundary
condition)
Hormone sensitive
Lipase
HSL 100 (Fixed boundary
condition)
Lipoprotein Lipase LPL 100 (Fixed
boundary
condition)
Hepatic Tissue Species and Peripheral Tissue
Species
Cholesterol ester
hydrolase
CEH 100 (Fixed
boundary
condition)
acyl coenzyme A: cholesterol
acyltransferase
ACAT 100 (Fixed
boundary
condition)
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the overall behaviour of the system, as the model indi-
cates that the dysregulation of cholesterol metabolism
with age may involve perturbations to several compo-
nents of this system. In tandem with investigating
changes to combinations of parameters, the model
may also be used to investigate combination therapy
that may help to mitigate the effects aging has on
cholesterol metabolism. For example, it would be
straightforward to include hypothetical interventions
that investigate different dietary regimes and also in-
clude the effects of variations in physical activity. For
example, based on available literature the simple as-
sumption could be made that consuming 3 g/day of
fibre reduces cholesterol absorption by 15% [57,58].
Therefore, the parameters could be adjusted accord-
ingly to reflect this. Similarly the effect of consuming
plant sterols, which are known to reduce cholesterol
absorption [59,60] could easily be investigated, as con-
sumption of 1.8 to 2.0 g/day of plant sterols has been
shown to lower both total and LDL-C concentrations
by 10% to 15%, respectively in a variety of different
population groups [61-63]. Thus, this could be investi-
gated by making alterations to the rate of cholesterol
absorption in the model.
Table 2 Summary of the reactions and parameter values
used in the model
Reaction Parameter Value Units
Cholesterol intake k1 1 mg/day
Bile salt release k2 6 mg/day
Hepatic return of bile salts k3 4.29 mg/day
Bile salt excretion k4 8.56 × 10
-1 mg/day
Bile salt synthesis k5 2.66 mg/day
Cholesterol absorption k6 5.29 × 10
-4 mg/day
Cholesterol excretion k7 5.29 × 10
-4 mg/day
Intestinal Nascent HDL
synthesis
k8 5 × 10
-4 mg/day
Hepatic cholesterol
storage
k9 1 mg/day
Release of stored Hepatic
cholesterol
k10 5.998 mg/day
Hepatic Nascent HDL
Synthesis
k11 5 × 10
-2 mg/day
VLDL cholesterol
formation
k12 1.6 × 10
-2 mg/dL/day
Synthesis of hepatic
LDL receptors
khrs 100 number/day
Hepatic LDL receptors
degradation
k13 1 × 10
-3 number/day
VLDL cholesterol hepatic
reuptake
k14 4.96 × 10
-3 mg/dL/day
IDL cholesterol formation k15 4.3 × 10
-1 mg/dL/day
IDL cholesterol hepatic
reuptake
k16 5.4 × 10
-2 mg/dL/day
LDL cholesterol formation k17 3.8 × 10
-1 mg/dL/day
Hepatic LDL receptors
uptake of LDL-cholesterol
k18 6.80 × 10
-2 mg/dL/day
Hepatic receptor independent
uptake of LDL-cholesterol
k19 5.0 × 10
-3 mg/dL/day
Peripheral LDL receptors
uptake of LDL-cholesterol
k20 6.75 × 10
-3 mg/day/day
Peripheral independent
uptake of LDL-cholesterol
k21 5.0 × 10
-6 mg/dL/day
Synthesis of peripheral
LDL receptors
kprs 100 number/day
Peripheral LDL receptors
degradation
k22 1 × 10
-2 number/day
Peripheral cholesterol
storage
k23 1.75 × 10
-2 mg/day
Release of stored peripheral
cholesterol
k24 1.07 × 10
-1 mg/day
Peripheral steroid production k25 5 × 10
-4 mg/day
HDL cholesterol formation k26 1.5 × 10
-5 mg/dL/day
CETP mediated transfer of
cholesterol to VLDL from HDL
k27 10 × 10
-3 mg/dL/day
CETP mediated transfer of
cholesterol to LDL from HDL
k28 1 × 10
-3 mg/dL/day
Reverse cholesterol
transport
k29 5.0 × 10
-2 mg/dL/day
Maximum rate of intestinal
cholesterol synthesis
ICSmax 1 × 10
2 mg/day
Table 2 Summary of the reactions and parameter values
used in the model (Continued)
Intestinal cholesterol
synthesis threshold
ICSt 3.120 × 10
2 mg/day
Sensitivity of intestinal
cholesterol synthesis
IS 5 Fitting
parameter
Maximum rate of biliary
cholesterol release
BCRmax 2 × 10
3 mg/day
Biliary cholesterol release
threshold
BCRt 5.55 × 10
4 mg/day
Sensitivity of the feedback
equation for biliary cholesterol
BS 5 Fitting
parameter
Maximum rate of hepatic
cholesterol synthesis
HCSmax 5 × 10
2 mg/day
Sensitivity of hepatic
cholesterol synthesis
HS 5 Fitting
parameter
Hepatic cholesterol
synthesis threshold
HCSt 9.39 × 10
4 mg/day
Maximum rate of peripheral
cholesterol synthesis
PCSmax 5 × 10
2 mg/day
Peripheral cholesterol
synthesis threshold
PPCt 8.0342 × 10
4 mg/day
Sensitivity of peripheral
cholesterol synthesis
PCSS 5 Fitting
parameter
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the finished product and several assumptions were made
during the building of the model, which were necessary
as considerable uncertainty still surrounds cholesterol
metabolism. For example, in the majority of cases the
functional form that best describes a reaction remains
unknown. We did however include a number of feed-
back and feed-forward equations to describe the behav-
iour of cholesterol and bile salt synthesis as these are
known to be subject to this type of action. At steady
state, parameter values attempted to reflect a generic
normolipididemic 20 year old male. Although param-
eter values were chosen for the model from available
published literature, the ranges of parameter values are
quite broad; however, given the nature and diversity of
the literature used this was unavoidable. On certain
occasions, parameter values simply did not exist, there-
fore reasonable values were chosen based on the pub-
lished literature. An area of the model that could be
developed further in the future is the kinetic para-
meters of the various enzymes involved in a number of
the reactions. Presently, most of these enzymes have ar-
bitrary values of 100 assigned to them to indicate that
they have ‘normal’ enzymatic activity. In the future it
would be worthwhile to use a resource such as
BRENDA to amend these enzymes to include km and
kcat values [64]. Despite these limitations it is hoped
that in the future the model will prove to be a useful
Cholesterol absorption (k6) as a percentage 
Figure 3 (A-E) Changes to cholesterol absorption in the range 30-85%. A-D) simulations of the model using MathSBML to show the
response of LDL-C to changes in the rate of efficiency of cholesterol absorption in the range 30-80% over a number of different time periods.
E) Steady-state levels of LDL-C for various different percentages of cholesterol absorption. This was generated with the software tool Copasi.
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that would be difficult, challenging or perhaps unethical
to conduct using convention means.
Building the model has highlighted priorities for
future experimental work, for example the need for
experimentalists to work closely with computational
modellers in order to generate appropriate quantitative
data that is of benefit to systems biology models
such as this one. Such data could be used to expand
and enhance our model leading to a better under-
standing of cholesterol metabolism, particularly theinterrelationship between cholesterol synthesis and ab-
sorption. This improved model could be used to gain
additional insights into the factors associated with
cholesterol metabolism that help to confer increased
longevity and healthy aging. Appropriate dietary inter-
vention strategies based on such models could be used
to decrease the risk of CVD and prolong healthy aging.
Models could be tailored for an individual’s dietary,
biochemical, genetic and social circumstances and as
such models can be coded in SBML they would be
relatively easy to extend, enhance and improve as more
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would be worthwhile combining our model with exist-
ing models, such as that of atherosclerosis progression
[65]. The portable nature of SBML also makes this a
very realistic possibility, especially if models that are
being merged have been designed using SBML [66,67].
Moreover, the model could be used to investigate
crosstalk between cholesterol metabolism and fatty acid
metabolism.
Conclusions
From the evidence presented in this paper it is clear that
cholesterol metabolism is a complex multi-component
system. Changes to this multi-component system as a
result of the ageing process can lead to high levels of
plasma cholesterol particularly LDL-C. There is an indis-
putable link between elevated levels of LDL-C and the
risk of developing atherosclerosis, with population stud-
ies indicating that LDL-C rises with age in both sexes in
a large number of individuals [5,68,69]. It is therefore
unsurprising that recent genetic studies have associated
lipid metabolism with longevity as it is apparent that
maintaining cholesterol balance is vital to cardiovascular
health [1,2,70,71].
We developed a whole-body computational model to
investigate the hypothesis that an increase in the rate
of cholesterol absorption and a reduction in the rate of
removal of LDL-C from the plasma were integral to
understanding the dysregulation of cholesterol metabol-
ism with age. We were of the opinion that existing
models of cholesterol metabolism were limited and
could not offer a sufficiently deep understanding of
how an entire biological system changes with age, thus
in this work a conscious effort was made to represent
the interactions throughout the body. Results from the
sensitivity analysis of the model indicated that the
model requires further fine-tuning in the future before
it could be used as a comprehensive tool for predicting
changes to LDL-C in response to dietary cholesterol/
fats and intrinsic aging. None the less we used the
model to investigate aging and it demonstrated that
changes to the rate of removal of LDL-C to half its ori-
ginal value at age 65 years resulted in a 116 mg/dL
rise in this cholesterol sub fraction, which is intimately
connected with CVD. The model contrasts with
other models of cholesterol metabolism in that it is
implemented in a whole-body fashion and provides a
template for building a quantitative systems level
understanding of cholesterol metabolism and its inter-
action with aging. In the future the model could con-
tribute to a better understanding of cholesterol
metabolism so that the wider population could benefit
in the same way as those individuals with exceptional
longevity have from an altered lipid profile.Methods
Deciding on model structure and the rationale for a
whole-body approach
Historically, mathematical modelling has been used to
investigate various aspects of both cholesterol and more
generally lipid metabolism; however to our knowledge
no model to date has been implemented to investigate
cholesterol metabolism mechanistically within a whole-
body framework, with the goal of understanding how in-
trinsic age-related biological changes affect this crucial
biological system. In order to appreciate the rationale
underpinning the whole-body approach that we adopted,
it is worthwhile examining some of the models of chol-
esterol metabolism that have been developed previously.
Additionally, it is worth exploring why these were un-
suitable for this work. In general these models can be
divided into three types; intracellular models of the chol-
esterol homeostasis genetic regulatory pathway; models
of lipoprotein dynamics, and compartmental models. If
we take the gene network approach, a recent version
involved a boolean network model that assigned 33 dif-
ferent components of intracellular cholesterol homeosta-
sis a boolean value. Simulations then led to the
representation of intracellular cholesterol homeostasis as
a boolean vector with each coordinate of the system de-
noting a biological species of the pathway [16]. It is easy
to appreciate the utility of this approach as a means of
better understanding the functioning of a gene regula-
tory network; however this strategy is not a mechanistic
approach. It is primarily a state based representation of
intracellular gene activity; therefore it is limited as it
does not include the different biological compartments
involved in cholesterol metabolism, such as absorption,
and hepatic/peripheral cholesterol synthesis. Nor does it
account for the synthesis of the various lipoproteins
such as VLDL, IDL, LDL and their subsequent interac-
tions with one another and with receptors both hepati-
cally and peripherally. Finally, and significantly for this
work it is difficult to imagine such models being able to
test a biological hypothesis that centres on three factors,
the aging process, cholesterol absorption and the re-
moval of LDL-C from the plasma.
If mathematical models focused on lipoprotein kinetics
are examined; one discovers a wide variety of models
that have represented varying degrees of cholesterol me-
tabolism and have centred to a large extent on the dy-
namics of the LDL receptor. Examples of such models
go back as far as the early 1980s when Goldstein et al.
presented a theoretical study of the interaction of LDL
receptors with coated pits [72,73]. These were followed
by other models of the same process [73] or more recent
slight adaptations of this process [74]. These models
have been beneficial from the point of view of elucidat-
ing the underlying dynamics which describe the
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underlying kinetics of this process. However, as with the
intracellular models, these models focus on one particu-
lar, isolated aspect of cholesterol metabolism and do not
portray the entire picture which is that cholesterol me-
tabolism involves the coordinated action of several dif-
ferent biological systems operating in unison throughout
the entire body.
The final approach that will be discussed is the compart-
mental methodology. Compartmental models, as the name
suggests, contain a number of compartments, each contain-
ing a well mixed material. Each compartment has a number
of connections leading into it and out of it. Biological mater-
ial can flow from one compartment to another, and it canFigure 4 Network diagram of the cholesterol metabolism model. The
3) excretion, 4) plasma, 5) hepatic and 6) peripheral tissue. The arrows repre
Enzymes are represented by blue spheres and their catalytic influence on the
reaction arrow. Synthesis is represented by the Greek symbol theta, while inh
the diet and bile is formed into micelles in the small intestine. Absorbed chol
plasma via VLDL. VLDL is in turn catabolised to LDL. Excess cholesterol from pbe added from the outside through a source, or it can be
removed through a sink. Such systems exchange material
with each other following certain rules [75]. These models
have advantages such as being able to examine in some de-
tail the interaction of lipoproteins and their derivatives. The
major limitation of these models is that they are not based
on underlying biological mechanisms; rather exchange rates
are based on experimental inferences. Therefore, as with the
previous approaches this method is also unsuitable for
representing a mechanistic whole-body of cholesterol
metabolism.
In order to overcome the limitations of the approaches
that have been discussed, it was decided to represent
cholesterol metabolism with the aid of biologicalmodel is laid out in 6 compartments, 1) intake, 2) intestinal tissue,
sent the flow of cholesterol around the system into its different forms.
reaction is indicated by a round arrow head coming into contact with a
ibition is represented by T -shaped arrows. In summary cholesterol from
esterol is then transported to the liver where it is exported into the
eripheral tissue is transferred to the liver via HDL.
Table 3 Breakdown of whole-body cholesterol synthesis
Compartment Cholesterol synthesised
Whole-Body (70 kg man) 700 mg/day
Peripheral Tissue 441 mg/day (70% of whole-body)
Intestine 49 mg/day(10% of peripheral)
Liver 210 mg/day
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logical counterparts. The compartments contained
quantitative details of the different forms of cholesterol.
These forms are present in very high numbers (e.g. in-
testinal, hepatic and peripheral cholesterol is present in
grams). This means that a stochastic approach would
not offer significant benefits, as the intrinsic stochasticity
in the system is negligible, and so a deterministic model
was considered more appropriate to represent these spe-
cies and their interactions. In order to implement this
deterministic solution, we created a series of ordinary
differential equations that were coupled and numerically
integrated. This type of approach has previously been
shown to be eminently suitable both for representing
mechanistic biological reactions and for dealing with the
time dimension associated with modelling the aging
process [13]. In order to build the ODEs, we first
needed to concisely represent the compartments and
the fundamental components of whole-body cholesterol
metabolism diagrammatically.
Construction of a network diagram
Whole-body cholesterol metabolism is a difficult
process to reason about directly; therefore the first step
in constructing a model of this nature was to assemble
a network diagram (Figure 4) using Systems Biology
Graphical Notation (SBGN). SBGN is a standardized
means of graphical representation of biological systems
that facilitated the drafting of a network diagram of
cholesterol metabolism in a clear and unambiguous
fashion [76]. This network diagram explicitly outlines
each of the compartments and the biological species
involved in whole-body cholesterol metabolism which
we have discussed. Each of the components of Figure 4
was then abbreviated and used to construct a series
of ODEs (Table 1 contains a summary of these
abbreviations).
Model assembly
Rationale for reaction forms
The assumption was made that a large number of the
reactions are of a first-order nature, where the rate of
the reaction is directly proportional to the concentra-
tion of one of the reactants. This assumption was made
to facilitate the evaluation of the model based on steady
states and to allow for the determination of parameters
when the model was compared to experimental data,
moreover the reaction form that best describes a large
number of these remains unknown. ODEs were con-
structed in an incremental fashion to meet certain
steady states, eventually giving rise to a unified series of
coupled ODEs and ultimately a whole-body mathemat-
ical model representing a generic twenty year old male.
The model was built using MathSBML [77]. MathSBMLis a software package that has been designed to work
with Mathematica (version 5.2) [78], a pre-existing
commercial software package developed to perform nu-
meric, algebraic, graphical and many other tasks. In
addition the software tool Copasi was used to perform
some of the parameter scans and steady state examina-
tions of the model [79]. The next section outlines the
assembly of the ODEs and the biological functions that
lie at their core. Additionally, the reasoning for the in-
clusion of each of the species in Figure 4 will be
detailed along with the quantitative data that was used
to make inferences about each of the steady states that
these species gave rise to.Cholesterol intake
As whole-body cholesterol metabolism was being dealt
with, it was important first to include the dietary intake
of cholesterol. According to Henderson et al. the average
amount of cholesterol ingested daily in the UK by a male
is 304 mg/day [80]. Cholesterol intake was assigned the
rate k1 and set at an initial value of 1. While dietary
cholesterol [DC] had its initial condition set to a fixed
value of 304.Cholesterol synthesis
Dietary cholesterol joins synthesised intestinal choles-
terol. Additionally, cholesterol is also synthesised
throughout the body [81]. To determine the daily rates
of synthesis in each compartment, whole-body choles-
terol synthesis was first calculated. According to Diets-
chy et al. humans synthesise 10 mg/kg of cholesterol
daily, therefore a 70 kg man synthesises 700 mg/day
[81]. The amount of cholesterol synthesis that can be
attributed to the liver, intestine and remaining peripheral
tissue is uncertain [81]. Therefore, whole-body synthesis
of cholesterol for a 70 kg man was based on the assump-
tion that 70% of cholesterol synthesis takes place in
the peripheral tissue and that 10% of this occurs in the
intestine [82] (Table 3). This data was then used to make
inferences about inter-compartmental cholesterol syn-
thesis and functional relationships were derived to de-
scribe cholesterol synthesis in each compartment.
Firstly, intestinal cholesterol synthesis was represented
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max represents the maximum amount of cholesterol that
can be synthesised by the intestine in a day, IC repre-
sents intestinal cholesterol. ICt represents the intestinal
cholesterol synthesis threshold and IS is a fitting param-
eter that represents the sensitivity of the negative feed-
back. It was assumed that the maximum rate of
intestinal cholesterol synthesis would be 100 mg/day
(Figure 5, graph A).
Intestinal cholesterol Synthesis ¼ ICSmax
1þ IC=ICtð ÞIS
ð1Þ
We also derived similar functions for both hepatic and
peripheral synthesis (equations 2 &3, respectively).
HCSmax and PCSmax represent the maximum amount of
cholesterol that can be synthesised daily in the hepaticFigure 5 (A-D) Functions and simulations associated with model build
cholesterol synthesis. C and D) Graphs of the functions for hepatic and per
hepatic cholesterol versus biliary cholesterol release state values being reacand peripheral compartments respectively. HCSt and
PPCt represent hepatic and peripheral daily rates of syn-
thesis thresholds respectively and HS and PCSS are fit-
ting parameters that represent the sensitivity of the
feedback in the two respective compartments. Based on
experimental data it was assumed that the maximum
daily rate of cholesterol synthesis in the liver would be
500 mg/day, while the maximum rate of peripheral chol-
esterol synthesis was also estimated to be 500 mg/day
(Figure 5, graphs B and C).
Hepatic cholesterol synthesis ¼ HCSmax
1þ HFC=HCStð ÞHS
ð2Þ
Peripheral cholesterol synthesis ¼ PCSmax
1þ PFC=PPCtð ÞPCSS
ð3Þing. A) Graph of concentration of intestinal cholesterol versus
ipheral cholesterol synthesis respectively. D) Graph of concentration of
hed for IDL-C and VLDL-C, respectively.
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According to Grundy and Metzger dietary cholesterol
also mixes intestinally with  1200 mg/day of biliary
cholesterol [83]. Therefore, a functional relationship was
derived to describe the release of biliary cholesterol. This
was done using a feed-forward equation (equation 2) as
by nature this biological interaction is feed-forward.
BCRmax represents the maximum daily release of biliary
cholesterol. BCRt represents the threshold of release of
biliary cholesterol and HFC represents the hepatic pool
of free cholesterol. Based on experimental data it was
assumed that the maximum rate of release of biliary
cholesterol would be 2000 mg/day (Figure 5, graph D)
[83].
Release of biliary cholesterol ¼ BCRmax
1þ BCRt=HFCð ÞBS
ð4Þ
Estimating the steady-state levels of cholesterol in each
compartment
It was necessary to estimate the steady-state level of
cholesterol in each compartment. According to Soars
et al. in mammals this usually falls within the range of
100-200 mg/100 g of intestine. Also according to Soras
et al. humans contain 30 g of intestine per kg of body
weight [84]. The concentration of cholesterol in the in-
testine was determined based on several assumptions;
firstly it was assumed that there is 150 mg of choles-
terol/100 g of intestine and secondly the assumption was
made that the hypothetical individual weighed 70 kg.
Details of this calculation are provided in Table 4.
Bile salts- hepatic synthesis and enterohepatic circulation
Bile salts are synthesised from the hepatic pool of free
cholesterol [HFC] at a rate of 400 mg/day, while the
hepatic bile salt pool [HBS] contains bile salt in the re-
gion of 4000 mg. This pool is released on average
four to six times per day into the small intestine. Thus,
a total of 24000 mg of bile salts enter the smallTable 4 Calculating the steady-state level of intestinal
cholesterol
The steady-state level of intestinal cholesterol
Weight of intestine 70*30=2100 g
Number of 100 g segments in intestine 2100/100=21
Total amount of cholesterol
equals the number of
100 g segments times 150 mg
21*150 mg
Total 3150 mgintestine daily. The synthesis of bile salts is subject
to negative feedback as the bile salt pool increases.
Based on this information a reciprocal type function
was derived to represent the production of bile salts
(equation 5). Where k5 is the rate constant for the
hepatic production of bile salts.
Hepatic Production of Bile Salts ¼ k5 HFC½ 
HBS½  ð5Þ
Almost all bile salts are reabsorbed (23600 mg/day)
and return to the liver, while the remainder (400 mg/
day) are excreted [85]. Bile salt release was assigned the
rate constant k2, while the hepatic return of bile salts
was assigned the rate constant k3. This rate was
dependent on the concentration of intestinal bile salts
[IBS] and the concentration of [IC]. The excretion of
bile salts [EBS] was assigned the rate constant k4. Put-
ting this information together, ODEs 1 and 2 were
assembled to describe how hepatic and intestinal bile
salts change with time.
d HBS½ 
dt
¼ k5 HFC½ 
HBS½ 
 
þ k3 IBS½  IC½ 
 k2 HBS½  ODE 1ð Þ
d IBS½ 
dt
¼ k2 BSP½   k3 IBS½  IC½   k4 IBS½  ODE 2ð Þ
Cholesterol absorption and excretion
The rate of cholesterol absorption and excretion depend
on the concentration of intestinal bile salts. Over the
years there has been controversy as to whether there is a
difference between the absorption of dietary cholesterol
and endogenously derived cholesterol. It is now accepted
that they form an indistinguishable intestinal pool [54].
An assumption was made based on experimental data
that 50% of cholesterol in the small intestine whether itTable 5 Flux of cholesterol into and out of the small
intestine on a daily basis
Contribution Amount in mg/day
Diet 304
Biliary cholesterol 1200
Intestinal synthesis 49
Total 1553
Absorbed  776.5
Excreted  776.5
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absorbed in a normal individual each day while 50%
would be excreted [21,86]. Table 5 presents a summary
of the estimated flux of cholesterol into and out of the
small intestine on a day to day basis. The daily rates of
cholesterol absorption and excretion were represented
by the rate constants k6 and k7 respectively, and thus we
were able to derive ODEs 3 and 4 that represent the
change with time of [IC] and excreted cholesterol [EC],
respectively.
d IC½ 
dt
¼ k1 DC½  þ BCRmax
1þ BCRt=HFCð ÞBS
 !
 k6 IBS½  IC½   k7 IBS½  IC½ 
þ ICSmax
1þ IC=ICtð ÞIS
 !
ODE 3ð ÞFigure 6 (A-E) Outputs and steady states associated with model build
was constructed initially. It shows the faecal excretion of both cholesterol a
steady state values being reached for both the hepatic cholesterol pool an
steady state levels of LDL-C, IDL-C and VLDL-C.d EC½ 
dt
¼ þk7 IBS½  IC½  ODE 4ð Þ
Simulations of the mini model
At this stage it was critical to create a mini-model, as de-
termination of parameter values becomes increasingly
complicated as models gain in size and complexity. The
parameters for the mini model were determined using the
baseline data outlined and the ODEs were numerically
solved using MathSBML. Figure 6, graph A, shows the
amount of cholesterol and bile salts excreted over a 100
day period. This output from the mini-system confirmed
that the intestinal and intake compartments, and part of
the hepatic compartment were behaving in a biologically
realistic manner, thus further compartments and species
were added to the system. It is important to note that the
hepatic pool of cholesterol was fixed at a value of 100 dur-
ing these simulations to facilitate parameterisation.ing. A) Graph of the output from a simulation of the mini model that
nd bile salts over a 100 day period. B and C) Graphs showing the
d hepatic cholesterol esters respectively. D and E) Graphs showing
Table 6 Outlining how the concentration of cholesterol in the liver was determined (Non obese subjects (n=19))
Liver sample Liver homogenate Liver microsomes Total
Mean free cholesterol 42.4 nmol/mg 24.7 nmol/mg 67.1 nmol/mg
Mean esterified cholesterol 9.9 nmol/mg 8.6 nmol/mg 18.5 nmol/mg
Total Hepatic Cholesterol 115.6 nmol/mg
Molecular weight of cholesterol 386.66 Used to convert nmol to milligrams
∴ Total cholesterol 44.6979 μg/mg or 0.0446979 mg/mg
Total esters 7.1539 μg/mg or 0.0071532 mg/mg
∴ Total free cholesterol 37.5447 μg/mg or 0.0375447 mg/mg
Size of Human Liver = 1.5 kg [89] 1.5kg=1500000 mg
0.0446979 *1500000=67046.85 mg total cholesterol
0.0071532 * 1500000=10792.80 mg of cholesterol esters
0.0375447*1500000=56317.5 mg of free cholesterol
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hepatic compartment
It was now necessary to estimate the steady state level of
hepatic cholesterol. The amount of cholesterol in the liver
was determined using data from Sahlin et al., the molecu-
lar weight of cholesterol and the weight of an average
human liver [87]. Calculations are outlined in Table 6.
According to Cook humans weighing 70 kg contain 
140 g of cholesterol [88]. Based on the calculations in
Table 6 the assumption was made that half the cholesterol
in man resides in the liver, while the remainder resides in
peripheral tissue. The assumption was also made that 10 g
of cholesterol is stored as esters in each compartment.
The hepatic synthesis of cholesterol was previously esti-
mated to be 210 mg/day. When the hepatic pool of chol-
esterol increases, there is a rise in the conversion of
cholesterol to esterified cholesterol. This reaction is cata-
lysed by ACAT and the forward reaction was assigned the
rate constant k9. The reverse reaction is catalysed by chol-
esterol ester hydrolases (CEH) and was assigned the rate
constant k10. Both ACAT and CEH were given fixed vales
of 100 to represent ‘normal’ enzymatic activity. Thus,
based on this information we were able to derive ODEs 5
and 6 to describe the change in both the [HFC] and hep-
atic cholesterol esters [HCE] with time.
d HFC½ 
dt
¼ k19 þ k10 HCE½  CEH½ ð Þ
 BCRmax
1þ BCRt=HFCð ÞBS
 !
k12 HFC½   k5 HFC½ BSP½ 
 
 k9 HACAT½  HFC½ 
HCSmax
1þ HFC=HCStð ÞHS
 !
ODE 5ð Þd HCE½ 
dt
¼ k9 ACAT½  HFC½ 
 k10 HCE½  CEH½  ODE 6ð Þ
These ODEs were added to the system and the model
was re-parameterised by sequential adjustment of the
parameters in order to bring both hepatic cholesterol
esters and the hepatic pool of free cholesterol into a
steady-state (Figure 6, graphs B and C).
Hepatic release of very low density lipoprotein cholesterol
According to Glomset et al. the amount of cholesterol
secreted hepatically in VLDL is considered to be in the
region of 800 mg/day and could be as high as 3000 mg/
day [90]. Therefore, it was assumed that in the steady
state 1000 mg/day of cholesterol was incorporated into
VLDL. The rate of incorporation of cholesterol into
VLDL was assumed to be proportional to the concentra-
tion of hepatic cholesterol and this reaction was assigned
the rate constant k12.
The turnover of hepatic LDL receptors
According to Dietschy, the rate of lipoprotein removal
from the circulation by the liver is dependent on the
concentration of the lipoprotein and hepatic LDL recep-
tors (HLDLRs) [82]. Brown and Goldstein established
that the synthesis of HLDLRs is subject to inhibition by
the intracellular concentration of free cholesterol
[44,91]. Thus represented the synthesis of HLDLRs with
equation 6, where khrs is the rate constant for the syn-
thesis of HLDLRs.
Synthesis of hepatic LDL receptors
¼ khrs HLDLRs½ 
HFC½  ð6Þ
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HLDLRs present on a human organ such as the liver.
Although, the number has been estimated at a cellular
level, it was not feasible to try and determine it for a
whole-body model of cholesterol metabolism. Thus, an
arbitrary value of 100 was assigned to represent a fully
active complement of HLDLRs and the rate constant k13
was assigned to represent the rate of HLDLRs degrad-
ation. Thus, ODE 7 was derived to describe the turnover
of HLDLRs. It is important to note that this type of ap-
proach has been used previously to model this process,
whereby the regulation of receptor synthesis is handled
via reciprocal feedback due to cholesterol concentration
[92].
d HLDLRs½ 
dt
¼ khrs HLDLRs½ 
HFC½ 
 k13 HLDLRs½  ODE 7ð Þ
It is known that a certain amount of VLDL-C is
removed via HLDLRs [82]. It was difficult to obtain
quantitative data about this process; however the litera-
ture indicated that this is not the major route by which
cholesterol re-enters the liver. It was therefore assumed
that only a negligible amount of VLDL-C is taken up via
this avenue (100 mg/day) and was assigned the rate
constant k14.
Hepatic LDL receptor mediated removal of VLDL-C from the
plasma
The enzyme LPL acts on VLDLs to reduce them to IDLs
[93]. It was assumed that this process is dependent on
the concentration of LPL and of VLDL-C and was
assigned the rate constant k15. Thus, ODE 8 was derived
to represent the change with time of VLDL-C.
d VLDLC½ 
dt
¼ k12 HFC½   k14 HLDLRs½  VLDLC½ 
 k15 LPL½VLDLC ðODE 8½ Þ
Similar to VLDL-C, a certain amount of IDL-C re-
enters the liver via HLDLRs and the assumption was
made that this is  10% of the overall particle compos-
ition. IDLs are further catabolised to LDLs by the en-
zyme hormone sensitive lipase (HSL). The majority of
LDL-C ( 75%) is taken up by the liver, while the re-
mainder is removed by peripheral tissue. Based on the
literature it was assumed that receptor independent up-
take of LDL-C is of minor importance and accounts for
only 50 mg/day of LDL-C removed from the tissue [94-
96]. This value was split equally between the liver andperipheral tissue. Based on this information ODEs 9
and 10 were derived to describe the change in IDL-C
and LDL-C with time. k16 is the rate constant for re-
moval of IDLC via the hepatic receptor and k17 is the
rate constant for the formation of LDL-C, while k18 is
the rate constant for HLDLR uptake of LDL-C and k19
is the rate constant for the hepatic receptor independ-
ent uptake of LDL-C. Peripheral LDL receptor
(PLDLRs) and non-peripheral receptor uptake are
represented by the rate constants k20 and k21, respect-
ively.
d IDLC½ 
dt
¼ k15 LPL½  VLDLC½   k16 HLDLR½  IDLC½ 
 k17 HSL½  IDLC½  ðODE 9Þ
d LDLC½ 
dt
¼ k17 HSL½  IDLC½   k18 LDLC½  HLDLRs½ 
 k19 LDLC½   k20 LDLC½  PLDLRs½ 
 k21 ODE 10ð Þ
Parameterisation to establish the steady states of LDL-C,
IDL-C VLDL-C
As the system had now increased in size significantly,
further simulations were completed to establish the
steady-state levels of the various species. Again the
model was re-parameterized using the data outlined and
the system numerically solved with MathSBML. After
adjustment of the parameters LDL-C, IDL-C and VLDL-
C entered steady states based on known literature values
(Figures 6, graphs D and E). It is important to note that
the values of both the peripheral pool of free cholesterol
(PFC) and PLDLRs were held at fixed arbitrary values of
100 to facilitate this process.
Further additions to the peripheral compartment
Once the first three compartments demonstrated reli-
able biological outputs, the final phase of model building
involved the addition of the peripheral compartment.
Table 7 outlines how the amount of cholesterol in the
peripheral tissue was calculated based on previous calcu-
lations for the amount of cholesterol in the liver and in-
testine. Previously, the rate of peripheral cholesterol
synthesis was estimated to be 441 mg/day. This was
completed in exactly the same manner as for the
hepatic pool, where the rate constants kprs represents
the synthesis of PLDLRs, k22 represents the degradation
of PLDLRs, k23 represents the formation of peripheral
cholesterol esters (PCE) and k24 is the release of
stored peripheral cholesterol. Additionally, according
to Myant, a certain amount of cholesterol can be con-
verted to steroid hormones. For example, a normal
Table 7 Calculation of cholesterol in the peripheral tissue
Tissue Concentration
Liver 70000 mg
Intestine 3120 mg
Remaining cholesterol in
peripheral tissue
70000-3120= 66880 mg
Liver 10000 mg of stored
cholesterol, which represents
14% of overall hepatic cholesterol
Peripheral tissue Assuming 14% is stored here:
14% of 66880=3963.2 mg
Peripheral free
cholesterol
66880-9363.2=57516.8 mg
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and gonadal hormones [62]. As this loss has to be
replaced, this was included in the model by the addition
of the rate constant k25 which represents steroid hor-
mone synthesis (PSS), which was in essence a sink spe-
cies. ODEs 11 and 12 were then derived. Again at this
point the model was re-parameterised and steady-states
produced.
d PCE½ 
dt
¼ k23 ACAT½  PFC½ 
 k24 PCE½  CEH½  ODE 11ð Þ
d PFC½ 
dt
¼ k21  k25 þ k24 PCE½  CEH½ 
 k23 ACAT½  PFC½  PCSmax
1þ PFC=PFCtð ÞPCSS
þ k20 LDLC½ ½PLDLRs ðODE 12Þ
Reverse cholesterol transport and the final steps to a
whole-body mathematical model
Based on current literature it was assumed that the pro-
duction of HDL-C is dependent on three factors; the
concentration of peripheral free cholesterol, the popula-
tion of nascent HDL particles and the activity of the en-
zyme LCAT which has a role to play in the conversion
of free peripheral cholesterol into cholesteryl esters
which are then sequestered into the core of a lipoprotein
particle, eventually making the newly synthesized HDL
particle. The enzyme is bound to HDLs and LDLs in the
blood plasma.
Firstly, the population of nascent HDLs had to be
represented. Nascent HDLs are synthesised in the intes-
tine. As extensive literature searches revealed little quan-
titative information related to this process, an arbitraryvalue of 100 mg/day was assigned for the synthesis of
nascent HDL. This value was then split evenly between
its two points of origin; the intestine and liver. ODE 13
was then derived where k8 represents the intestinal rate
of nascent HDL (NHDL) synthesis and k11 represents
the hepatic synthesis of NHDL.
d NHDL½ 
dt
¼ k8 þ k11 ODE 13ð Þ
Reverse cholesterol transport is important as it repre-
sents the only route for excess cholesterol generated in
the peripheral tissue to be removed from the body, ei-
ther by secretion into bile or by conversion into bile
acids [55]. In the steady state, RCT should equal the
rate of synthesis of cholesterol in the peripheral tissue
[41]. Previously the synthesis of cholesterol in the per-
ipheral tissue was calculated to equal 441 mg/day.
Therefore, 441 mg of cholesterol that originated in per-
ipheral tissue should enter the liver via HDL and this
return of cholesterol via HDL-C to the liver may follow
one of several routes. In the presence of CETP, a por-
tion of the HDL cholesterol is transferred to either
VLDL or LDL and ultimately returned to the liver via
HLDLRs; therefore it was assumed that 10% of the
cholesterol that is scavenged by HDL-C makes its way
to the liver via this path. Alternatively, HDL-C is deliv-
ered to the liver via scavenger receptor class B1 [SRB1].
Thus based on this information the change in HDL-C
with time was represented by ODE 14, where k26 is the
rate constant for the enzymatic dependent scavenging
of cholesterol from the peripheral compartment, k27 is
the rate constant for the CETP dependent transfer of
cholesterol to VLDL and k28 is the rate constant for the
CETP mediated transfer of cholesterol to LDL. Finally,
k29 is the rate constant for reverse cholesterol trans-
port.
d HDLC½ 
dt
¼ k26 LCAT½  NHDL½  PFC½ 
 k27 CETP½  HDLC½ 
 k28 CETP½  HDLC½ 
 k29 HDLC½  SRB1½  ODE 14ð Þ
Updating of ODEs 5 and ODE6
ODE 5 and ODE 6 were updated to include the changes
described above. Again the system was re-parameterized
and brought into a steady state to reflect these new
changes. HDL-C reached a steady state which was based
on the literature for normolipidemic male. All reactions
and parameters are summarised in Table 2.
d HFC½ 
dt
¼ k19 þ k10 HCE½  CEH½ ð Þ  BCRmax
1þ BCRt=HFCð ÞBS
 !
HCSmax
1þ HFC=HCStð ÞHS
 !
þ k6 IBS½  IC½ ð Þ þ k16 HLDLRs½  IDLC½ ð Þ þ
k18 HLDLRs½  LDLC½ ð Þ þ k29 HDLC½  SRB1½ ð Þ k14 HLDLRs½  VLDLC½ ð Þ
k12 HFC½   k5 HFC½ BSP½ 
 
 k9 ACAT½  HFC½  Updated ODE 5ð Þ
d PFC½ 
dt
¼ k21  k25 þ k24 PCE½  CEH½   k26 LCAT½  NHDL½  PFC½   k23 ACAT½  PFC½  þ
PCSmax
1þ PFC=PFCð ÞPCSS þ k20 LDLC½ ½PLDLRs ðUpdated ODE 6Þ
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Biomodels database
The model was coded into SBML using an export function
in MathSBML (Additional file 2). Unlike computer lan-
guages such as C, C++ and Java, SBML was not designed
to be coded manually; instead a number of tools are avail-
able that automatically generate SBML. The code can then
be exchanged between tools supporting SBML [17]. In
this case the model code was transferred into the software
tool Copasi to facilitate parameter scanning [79]. Please
note that when the ODEs are integrated in Copasi using
the initial conditions, LDL-C enters a slightly higher
steady-state than it does with MathSBML. In addition the
model was submitted to the Biomodels database http://
www.ebi.ac.uk/biomodels-main/ to facilitate its updating
and future exchange (MODEL1206010000).
Additional files
Additional file 1: Copasi file of Whole-Body Model of Cholesterol
Metabolism.
Additional file 2: SBML file of Whole-Body Model of Cholesterol
Metabolism.
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